CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content

Zoledronic acid

Last Updated: July 20, 2011
Result type: Reports
Project Number: S0242
Product Line: Common Drug Review

Generic Name: Zoledronic acid

Brand Name: Aclasta

Manufacturer: Novartis Pharmaceuticals Canada Inc.

Indications: Osteoporosis (postmenopausal women)

Submission Type: Request For Advice

Project Status: Complete

Date Recommendation Issued: November 16, 2011

Recommendation Type: List with clinical criteria and/or conditions